About Bioventus Inc.
https://www.bioventus.comBioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
CEO
Robert E. Claypoole
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 68
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
ESSEX WOODLANDS MANAGEMENT, INC.
Shares:13.02M
Value:$100.79M
JUNIPER INVESTMENT COMPANY, LLC
Shares:6.94M
Value:$53.71M
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:5.81M
Value:$44.97M
Summary
Showing Top 3 of 147
About Bioventus Inc.
https://www.bioventus.comBioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $138.65M ▼ | $80.73M ▼ | $3.15M ▼ | 2.28% ▼ | $0.05 ▼ | $22.25M ▼ |
| Q2-2025 | $147.66M ▲ | $83.72M ▲ | $7.46M ▲ | 5.05% ▲ | $0.11 ▲ | $29.86M ▲ |
| Q1-2025 | $123.88M ▼ | $78.19M ▼ | $-2.64M ▼ | -2.13% ▼ | $-0.04 ▼ | $15.96M ▼ |
| Q4-2024 | $153.64M ▲ | $94.67M ▲ | $-156K ▲ | -0.1% ▲ | $-0 ▲ | $21.63M ▲ |
| Q3-2024 | $138.96M | $89.48M | $-4.82M | -3.47% | $-0.07 | $16.98M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $42.16M ▲ | $701.59M ▼ | $494.34M ▼ | $166.1M ▲ |
| Q2-2025 | $32.91M ▲ | $706.79M ▲ | $505.49M ▼ | $161.24M ▲ |
| Q1-2025 | $22.8M ▼ | $691.41M ▼ | $505.94M ▼ | $148.14M ▲ |
| Q4-2024 | $41.58M ▼ | $727.96M ▼ | $542.35M ▼ | $147.94M ▼ |
| Q3-2024 | $43.07M | $769.49M | $582.66M | $148.74M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.15M ▼ | $30.1M ▲ | $-473K ▲ | $-19.98M ▼ | $9.25M ▼ | $29.63M ▲ |
| Q2-2025 | $9.27M ▲ | $25.94M ▲ | $-1.37M ▼ | $-14.66M ▼ | $10.11M ▲ | $25.25M ▲ |
| Q1-2025 | $-3.32M ▼ | $-19.33M ▼ | $-826K ▼ | $947K ▲ | $-18.78M ▼ | $-20.16M ▼ |
| Q4-2024 | $-318K ▲ | $19.32M ▲ | $24.1M ▲ | $-42.85M ▼ | $-1.49M ▼ | $18.75M ▲ |
| Q3-2024 | $-5.42M | $10.32M | $-64K | $362K | $11.08M | $10.25M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 International Segment | $20.00M ▲ | $10.00M ▼ | $20.00M ▲ | $20.00M ▲ |
 US Segment | $140.00M ▲ | $110.00M ▼ | $130.00M ▲ | $120.00M ▼ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 NonUS | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $10.00M ▼ |
 UNITED STATES | $140.00M ▲ | $130.00M ▼ | $120.00M ▼ | $110.00M ▼ |
CEO
Robert E. Claypoole
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 68
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
ESSEX WOODLANDS MANAGEMENT, INC.
Shares:13.02M
Value:$100.79M
JUNIPER INVESTMENT COMPANY, LLC
Shares:6.94M
Value:$53.71M
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:5.81M
Value:$44.97M
Summary
Showing Top 3 of 147